# Fasting Study of Mercaptopurine 50 mg and Purinethol® Tablets 50 mg

> **NCT00648336** · PHASE1 · COMPLETED · sponsor: **Mylan Pharmaceuticals Inc** · enrollment: 60 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Mercaptopurine 50 mg
- **DRUG:** Purinethol® Tablets 50 mg

## Key facts

- **NCT ID:** NCT00648336
- **Lead sponsor:** Mylan Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** 2003-12
- **Final completion:** 2003-12
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00648336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00648336, "Fasting Study of Mercaptopurine 50 mg and Purinethol® Tablets 50 mg". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT00648336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*